<article id="leonard_2009" class="slide" data-ag-slide-name="Leonard 2009">
    <div class="basic">
      <h1 class="title-fix" data-ag-editable="Leonard 2009 Main Title">Neulasta<sup>®</sup> allows you to achieve sufficient chemotherapy dose intensity for over 85% of your patients even after they have experienced a neutropenic event<sup>1*</sup></h1>
      <div id="rdi_page2_top">
         <p class="red_subtitle" data-ag-editable="Leonard 2009 Top Copy">With an RDI ≥85%, breast cancer patients have a significantly higher chance of 10 year survival<sup>2</sup></p>
      </div>
      <div id="rdi_page2_data_holder">
         <table width="800" border="0" cellspacing="0" cellpadding="0">
            <tr>
               <td width="184">&nbsp;</td>
               <td width="550" id="rdi_page2_data_table_top" class="rdi_page2_data_table_green_bg" align="center" valign="middle"><p data-ag-editable="Leonard 2009 Table Top Copy">Proportion of patients with neutropenic<br />events achieving RDI ≥85%</p></td>
               <td width="80">&nbsp;</td>
            </tr>
            <tr>
               <td>
                  <div id="rdi_page2_data_table_section1_title" class="rdi_page2_data_table_green_bg">
                     <ul class="red_dot_list">
                        <li data-ag-editable="Leonard 2009 Table Left Title 1">Neulasta<sup>®</sup><br />(1 per cycle)</li>
                     </ul>
                     <div id="rdi_page2_section1_clock"></div>
                  </div>
                  <div id="rdi_page2_data_table_section2_title">
                     <ul class="red_dot_list">
                        <li data-ag-editable="Leonard 2009 Table Left Title 2">Daily Filgrastim<br />(7 per cycle)</li>
                     </ul>
                     <div id="rdi_page2_section2_clock_holder">
                        <div id="rdi_page2_section2_clock"></div>
                     </div>
                  </div>
                  <div id="rdi_page2_data_table_section3_title">
                     <ul class="red_dot_list">
                        <li data-ag-editable="Leonard 2009 Table Left Title 3">No G-CSF</li>
                     </ul>
                  </div>
               </td>
               <td>
                  <div id="rdi_page2_section1_image"></div>
                  <div id="rdi_page2_section2_image"></div>
                  <div id="rdi_page2_section3_image"></div>
               </td>
               <td class="rdi_page2_data_table_pink_bg"><p data-ag-editable="Leonard 2009 Table Right Copy">Proportion of patients with neutropenic event NOT <br />achieving sufficient RDI (&lt;85%)</p></td>
            </tr>
         </table>
         <div id="rdi_page2_graph_ref" data-ag-editable="Leonard 2009 Table Bottom Copy">Adapted from Leonard R <em>et al</em>. Eur J Cancer Suppl 2009; 7(2):270</div>
      </div>
      <div id="rdi_page2_bottom_data" data-ag-editable="Leonard 2009 Bottom Copy">After initiation of G-CSF patients continued to receive G-CSF throughout all cycles</div>
    </div>
    <!-- Reference Information Starts -->
    <div class="lightbox_data" id="leonard_2009_refs">
       <div class="main_content_style">
          <p><strong data-ag-editable="Leonard 2009 References Title">References:</strong></p>
          <div data-ag-editable="Leonard 2009 References List">
             <ol>
                <li>Leonard R <em>et al</em>. Secondary Prophylaxis with G-CSF has a major effect on delivered dose intensity: The results of the UK NCRI/Anglo Celtic SPROG trial for adjuvant chemotherapy of breast cancer. Eur J Cancer Suppl 2009; 7(2):270</li>
                <li>Chirivella L <em>et al</em>. Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients. Breast Cancer Res Treat 2009; 114(3):479-484</li>
             </ol>
          </div>
          <p data-ag-editable="Leonard 2009 References Bottom Copy">* In a prospective study, 407 patients with early stage breast cancer receiving standard dose adjuvant chemotherapy were randomized at first neutropenia event* to management with dose delays or dose reductions versus G-CSF as secondary prophylaxis. After initiation of G-CSF patients continued to receive G-CSF throughout all cycles<sup>1</sup></p>
       </div>
    </div>
    <!-- Reference Information Ends -->
</article>